These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 19419313)

  • 21. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women.
    Recker RR; Gallagher R; MacCosbe PE
    Mayo Clin Proc; 2005 Jul; 80(7):856-61. PubMed ID: 16007889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
    Cramer JA; Amonkar MM; Hebborn A; Altman R
    Curr Med Res Opin; 2005 Sep; 21(9):1453-60. PubMed ID: 16197664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence.
    Rabenda V; Hiligsmann M; Reginster JY
    Expert Opin Pharmacother; 2009 Oct; 10(14):2303-15. PubMed ID: 19640210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Secondary prevention of osteoporosis: Calcium, Vitamin D and bisphosphonate prescribing following distal radial fracture.
    Talbot JC; Elener C; Praveen P; Shaw DL
    Injury; 2007 Nov; 38(11):1236-40. PubMed ID: 17572417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The economics of fragility fractures in West Virginia.
    Pfister AK; Sale WG; Shaukat S
    W V Med J; 2009; 105(4):10-3. PubMed ID: 19585898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis.
    Makras P; Hamdy NA; Zwinderman AH; Ballieux BE; Papapoulos SE
    Bone; 2009 May; 44(5):766-71. PubMed ID: 19442613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature.
    Fleurence RL; Iglesias CP; Johnson JM
    Pharmacoeconomics; 2007; 25(11):913-33. PubMed ID: 17960951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An integrated approach: bisphosphonate management for the treatment of osteoporosis.
    Owens G; Jackson R; Lewiecki EM
    Am J Manag Care; 2007 Dec; 13 Suppl 11():S290-308; quiz S309-12. PubMed ID: 18095779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
    Miller PD
    Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
    Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM
    Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The economics of improving medication adherence in osteoporosis: validation and application of a simulation model.
    Patrick AR; Schousboe JT; Losina E; Solomon DH
    J Clin Endocrinol Metab; 2011 Sep; 96(9):2762-70. PubMed ID: 21733991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preferences of patients receiving bisphosphonates--how to influence the therapeutic adherence.
    Payer J; Killinger Z; Sulková I; Celec P
    Biomed Pharmacother; 2008 Feb; 62(2):122-4. PubMed ID: 17888616
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of bisphosphonate therapy in a community setting.
    Feldstein AC; Weycker D; Nichols GA; Oster G; Rosales G; Boardman DL; Perrin N
    Bone; 2009 Jan; 44(1):153-9. PubMed ID: 18926939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A review of the cost effectiveness of bisphosphonates in the treatment of post-menopausal osteoporosis in Switzerland.
    Lippuner K; Pollock RF; Smith-Palmer J; Meury T; Valentine WJ
    Appl Health Econ Health Policy; 2011 Nov; 9(6):403-17. PubMed ID: 21910511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
    Ettinger MP
    Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Markov model simulation of the impact of treatment persistence in postmenopausal osteoporosis.
    Cotté FE; Fautrel B; De Pouvourville G
    Med Decis Making; 2009; 29(1):125-39. PubMed ID: 18566486
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trends and determinants of antiresorptive drug use for osteoporosis among elderly women.
    Perreault S; Dragomir A; Desgagné A; Blais L; Rossignol M; Blouin J; Moride Y; Ste-Marie LG; Fernandès JC
    Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):685-95. PubMed ID: 15645517
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bisphosphonate therapy for osteoporosis: combining optimal fracture risk reduction with patient preference.
    Beard MK
    Curr Med Res Opin; 2012 Jan; 28(1):141-7. PubMed ID: 22103779
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem.
    Cramer JA; Silverman S
    Am J Med; 2006 Apr; 119(4 Suppl 1):S12-7. PubMed ID: 16563936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.